A Phase 1/2 interventional study of [225Ac]Ac-FL-261 and [225Ac]Ac-FL-261 in Solid Tumor, NSCLC and Colorectal Cancer, sponsored by Full-Life Technologies UK Limited. Recruiting at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Full-Life Technologies UK Limited · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,339 studies in Colorectal Neoplasms with a site in United States — 418 open to participants now, 630 under way, 30 of them phase 3. Colorectal Neoplasms · United States.
Among the 2,339 studies in Colorectal Neoplasms with a site in United States, this one is the 510th largest by planned enrollment of the 1,932 interventional ones that give a count, is one of 118 that started in 2026, is one of 266 in phase 1/2, reaches primary completion later than 588 of the 628 other live ones, and was the 2,328th registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →418 of the 2,339 studies in Colorectal Neoplasms with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18+
Exelixis · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 40–80 · Men only
University of Pennsylvania · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,339 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 817 · Phase 2 791 · Phase 3 132 · Phase 4 19
First in 1981; this study’s year is marked. 118 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 208 is above the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 64 across the 1,932 interventional studies, 221 across the 324 observational. Of the 1,562 that completed or were terminated, 550 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
885 of 2,339 have an industry lead sponsor. The 10 most frequent:
Full-Life Technologies UK Limited is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Full-Life Technologies UK Limited has 1 study filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
228 of the studies in Colorectal Neoplasms with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05141721Phase 3Seattle Project CorporationA Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer | 2027-03 |
| NCT04428905Phase 3City of Hope Medical CenterSelf-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal Cancer | 2027-03-31 |
| NCT02997228Phase 3National Cancer Institute (NCI)Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study | 2027-06-01 |
| NCT01349881Phase 3SWOG Cancer Research NetworkS0820, Adenoma and Second Primary Prevention Trial | 2027-09-15 |
| NCT03796884Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityLinaclotide in Treating Patients With Stages 0-3 Colorectal Cancer | 2026-11 |
Add all 228 to your calendar (.ics) → With an account.
Among the 2,339 studies in Colorectal Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a first-in-human, multicenter, open-label Phase 1/2 study designed to evaluate the safety, efficacy, and tolerability of [225Ac]Ac-FL-261, a targeted radioligand therapy directed at c-MET, in participants with advanced or metastatic solid tumors. Phase 1 will identify the recommended dose through dose escalation, followed by a randomized comparison of two candidate dosing regimens (dose optimization). In Phase 2, the selected dose will be tested in independent cohorts by tumor type.
Phase 1: Dose Escalation
[225Ac]Ac-FL-261 will be administered at increasing doses in participants with non-squamous non-small cell lung cancer (ns-NSCLC) to identify the maximum tolerated dose (MTD) based on a BOIN design.
Phase 1 - Dose Optimization
After Dose Escalation is complete, 2 treatment regimens will be compared to select the optimal treatment regimen (OTR) between them.
Phase2
Participants with ns-NSCLC, colorectal cancer, head and neck cancer and cholangiocarcinoma will be enrolled into separate cohorts to estimate the efficacy of [225Ac]Ac-FL-261 at the OTR in each indication.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
They received an experimental () anti-cancer treatment within the last 4 weeks or within 5 half-lives of that treatment (whichever period is longer).
They received radiation therapy too recently, including:
They still have significant side effects from previous cancer treatments.
They have serious heart disease, including:
They have an active infection that requires treatment, including:
However, some people with chronic HIV, hepatitis B, or hepatitis C may be allowed to participate if their infection is well controlled and approved by the study doctor.
They have had another type of active cancer within the last 3 years, apart from the cancer being studied.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dose escalation will use the Bayesian Optimal Interval (BOIN) design to determine the maximum tolerated dose (MTD).
Drug: [225Ac]Ac-FL-261
Randomized comparison of two candidate dosing regimens to select the optimal treatment regimen (OTR) for Phase 2.
Drug: [225Ac]Ac-FL-261
The optimal dose and regimen is tested in separate cohorts by tumor type, using a two-stage design.
Drug: [225Ac]Ac-FL-261
Dose escalation per BOIN design to determine MTD.
Two candidate dosing regimens, randomized 1:1 (30 participants per arm)
* Non-squamous non-small cell lung cancer (NSCLC) * Colorectal cancer (CRC) * Head and neck squamous cell carcinoma (HNSCC) * Cholangiocarcinoma
Phase 1 Dose Escalation: Incidence of Dose-Limiting Toxicities (DLTs)
Time frame: Until 28 days after the first injection of [225Ac]Ac-FL-261]
2. Phase 1 Dose Escalation and Phase 1 Dose Optimization: Type, frequency, and severity of adverse events (AEs) and serious adverse events (SAEs) using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v6.0
Time frame: From ICF signature and up to 35 days after the last dose of study treatment for all AEs/SAEs. Thereafter, only AEs of special interest (AESIs) and related SAEs will be reported (up to 5 years)
Overall response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Time frame: Every 6 weeks for 24 weeks, then every 12 weeks until disease progression (up to 5 years)
Phase 1 and Phase 2: Duration of response (DoR)
Time frame: Every 6 weeks for 24 weeks, then every 12 weeks, until disease progression (up to 5 years)
Phase 1 and Phase 2: Disease control rate (DCR)
Time frame: Every 6 weeks for 24 weeks, then every 12 weeks, until disease progression (up to 5 years)]
Phase 1 and Phase 2: Progression-free survival (PFS) by RECIST v1.1
Time frame: Every 6 weeks for 24 weeks, then every 12 weeks, until disease progression (up to 5 years)
Phase 1 and Phase 2: Overall survival (OS)
Time frame: Every 6 weeks for 24 weeks, then every 12 weeks, until disease progression (up to 5 years)
Phase 1: ORR by RECIST v1.1
Time frame: Every 6 weeks for 24 weeks, then every 12 weeks, until disease progression (up to 5 years)
Phase 1 and Phase 2: Peak plasma concentration (Cmax) of [225Ac]Ac-FL-261
Time frame: Phase 1: Up to Day 15 of Cycle 1 and Cycle 2 (each cycle is 28 days); and on the first day of Cycle 3 and Cycle 4. Phase 2: Up to Day 15 of Cycle 1
Phase 1 and Phase 2: Time to achieve Cmax (tmax)
Time frame: Phase 1: Up to Day 15 of Cycle 1 and Cycle 2; and on the first day of Cycle 3 and Cycle 4. Phase 2: Up to Day 15 of Cycle 1
Phase 1 and Phase 2: Area under the plasma concentration-time curve (AUC)
Time frame: Phase 1: Up to Day 15 of Cycle 1 and Cycle 2; and on the first day of Cycle 3 and Cycle 4. Phase 2: Up to Day 15 of Cycle 1
Phase 2: Type, frequency, and severity of AEs and SAEs using NCI CTCAE v6.0.
Time frame: From ICF signature and up to 35 days after the last dose of study treatment for all AEs/SAEs. Thereafter, only AESIs and related SAEs will be reported (up to 5 years)
Start is estimated for Dec 2026; primary completion for Jun 2030, 42 months later.
Of 158 industry-sponsored phase 1/2 interventional studies under Colorectal Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 82. This study's planned 42 months is below that.
Counting every sponsor, half of 260 studies reached it within 59 months; a quarter within 36 and three quarters within 87.
Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Dec 2026, on Nov 16, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Actinium-225
Full-Life Technologies UK Limited